Siltuximab is a chimeric (human-mouse) monoclonal immunoglobulin G1-kappa antibody produced in a Chinese hamster ovary (CHO) cell line by recombinant DNA technology.
Siltuximab prevents the binding of IL-6 to soluble and membrane-bound IL-6 receptors by forming high affinity complexes with human interleukin-6 (IL-6).
Its use is indicated for the treatment of adult patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.
MCD is a rare blood disorder caused by dysregulated IL-6 production, proliferation of lymphocytes, and subsequent enlargement of the lymph nodes.
It is administered as a 1 hour intravenous infusion every 3 weeks.
Applications:Suitable for use in ELISA and SDS-PAGE.
Other applications not tested.
Recommended Dilution:Optimal dilutions to be determined by the researcher.
Storage and Stability:May be stored at 4℃ for short-term only.
Aliquot to avoid repeated freezing and thawing.
Store at -20℃.
Aliquots are stable for 12 months after receipt.
For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
仕様
Size：100ug
抗体種類：Mab
宿主：human
Grade：Highly Purified
Purity：≥95%
Form：Supplied as a liquid in PBS, pH 7.5.
Specificity：Recognizes Siltuximab (IL6).
Isotype：IgG1,k
Calc Applications Abbrev：E
Immunogen：Recombinant protein corresponding to Chimeric/IL6 [Homo sapiens], expressed in CHO cells.
